• Option 1: Discussing VRX’s psoriasis drug brodalumab. With an upcoming PDUFA date set, how much will the drug’s troubled past impact its future?
• Option 2: Exploring the potential of TNXP’s fibromyalgia drug TNX-102 sl. What can we expect from the upcoming Phase 3 results and what type of impact would it have on the market? By Killian McKee, Slingshot Contributor This week covers the market potential …show more content…
Although brodalumab will likely receive FDA approval this fall, investors should still have some concerns about Valeant’s acquisition from Astrazeneca/Amgen. A suicide riddled trial history could come back to haunt brodalumab in the form of stricter than usual regualtions and limit Valeant’s market potential. Option 1 discusses the impact of brodalumab’s past on its potential to perform in the psoriasis …show more content…
Topical treatments (things like corticosteroids, moisturizers, and retinoids) are typically used to slow the rate at which skin cells build up in mild to moderate cases of psoriasis. Light therapy uses natural and artificial light to kill skin cells and slow buildup rates. Systemic medications involve oral or injected drugs aimed at treating moderate to severe cases by altering the immune system or reducing skin cell production. Although effective, many systemic medications have severe side effects, some of which include severe birth defects, blood cell reductions, high blood pressure, and liver damage. Clearly, a large unmet need exists for a drug capable of tackling psoriasis, especially more serious cases, without seriously adverse side